Sector News

BD picks up Spanish developer of minimal residual disease cancer blood tests

February 4, 2022
Life sciences

After serving as a longtime provider of screening assays and instruments for diagnosing cancer, BD is broadening its reach in oncology by acquiring tests that monitor patients for recurrence following treatment.

The medtech company has bought Cytognos, a Spain-based developer of blood tests for tracking minimal residual disease—or the minuscule amounts of cancer cells left floating in the bloodstream while a patient is in remission.

The objective of the deal, made for an undisclosed amount, is to expand BD’s portfolio of flow-cytometry-powered diagnostics for blood cancers including lymphoma, leukemia and multiple myeloma. The transaction covers immune system assessment tests and informatics solutions for oncologists as well.

The acquisition also carries BD into a growing research space of supersensitive tests for minimal residual disease—where companies such as Illumina’s Grail and Exact Sciences’ Thrive Earlier Detection, among many others, are developing their own diagnostics focused on the repeated screening of cancer patients to track the effects of therapy.

“As the understanding and treatment of cancer evolves and improves, the importance of monitoring post remission cancer survivors has become paramount to improve patient outcomes,” Puneet Sarin, worldwide president of BD Biosciences, said in a statement.

Cytognos, previously a division of Spanish diagnostics company Vitro, will also grant BD exclusive access to a series of assays previously licensed from the EuroFlow Consortium, an independent network of hematology and immunology researchers from more than 20 universities and hospitals on the continent.

These flow cytometry tests would be added on top of ones that BD has procured from EuroFlow through its own 12-year licensing collaboration with the group.

Meanwhile, the 25-year-old Cytognos-owned diagnostic products have yet to undergo FDA review or enter the U.S. market; they previously have been available in Europe under a CE mark and in other countries.

by Conor Hale

Source: fiercebiotech.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.